Related Experiment Videos
Corrigendum: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or
Maria Rosario1, Jonathan L French2, Nathanael L Dirks2
1Clinical Pharmacology Department, Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
Journal of Crohn'S & Colitis
|February 1, 2018
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
The Efficacy and Safety of Etrasimod in Mildly to Moderately Active Ulcerative Colitis: Results From the Phase II GLADIATOR Trial.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
A decade of clinical data with vedolizumab: the past, present, and future.
Therapeutic advances in gastroenterology·2026
Modifiable lifestyle factors in early life and inflammatory bowel disease risk in two birth cohorts.
Journal of Crohn's & colitis·2026
BRD4 contributes to the cytokine-induced acquisition of an IL-13RA2-positive inflammatory fibroblast phenotype.
Journal of Crohn's & colitis·2026
Management of pediatric Crohn's disease: an ECCO-ESPGHAN guideline update.
Journal of Crohn's & colitis·2026
Baseline Gustave Roussy Immune Score and Survival in Extensive-Stage Small-Cell Lung Cancer Treated with First-Line Chemoimmunotherapy.
Cancer management and research·2026
Dissection of lymph node on longevity in breast and colorectal operation.
Bioinformation·2026